Fox Run Management, L.L.C. Apellis Pharmaceuticals, Inc. Transaction History
Fox Run Management, L.L.C.
- $608 Million
- Q1 2025
A detailed history of Fox Run Management, L.L.C. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 15,712 shares of APLS stock, worth $300,099. This represents 0.06% of its overall portfolio holdings.
Number of Shares
15,712Holding current value
$300,099% of portfolio
0.06%Shares
6 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$235 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$233 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$227 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$193 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$184 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.1B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...